A rare case of daratumumab-associated encephalopathy in multiple myeloma.
Immunotherapy
; 16(7): 447-452, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38440862
ABSTRACT
Aim:
Daratumumab, a CD38 monoclonal antibody, has been widely used in patients with multiple myeloma. Although a variety of adverse events have been reported, consciousness impairment has not been reported yet. We report a case of encephalopathy associated with daratumumab. Case presentation A 57-year-old male, diagnosed with relapsed multiple myeloma, was treated with daratumumab. He developed a loss of consciousness after the first administration. Cerebral spinal fluid and magnetic resonance imaging of the brain suggested encephalopathy.Conclusion:
It is recommended to be aware of rare but life threatening side effects of daratumumab. We present a case of rare encephalopathy characterized by consciousness disorder associated with daratumumab, which was successfully resolved on prompt institution of steroids, although the mechanism was unknown.
Daratumumab is a drug. It is used to treat multiple myeloma. Many patients use this drug. It has many side effects. But consciousness disorder is rare. A 57-year-old male was diagnosed with multiple myeloma. He was treated with daratumumab. He became unconscious after this treatment. Steroids helped his recovery.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Diseases
/
Multiple Myeloma
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Immunotherapy
Journal subject:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Year:
2024
Document type:
Article